

Amendments to the Claims:

Please amend claim 7 and add new claims 25-30. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Withdrawn): A pharmaceutical composition for treating a disease associated with one or more self-molecules present non-physiologically in a subject, the composition comprising:
 - (a) an immune modulatory nucleic acid comprising a hexamer region of the formula 5'-Purine-Pyrimidine-[X]-[Y]-Pyrimidine-Pyrimidine-3', wherein X and Y are any naturally occurring or synthetic nucleotides except that X and Y cannot be cytosine-guanine; and
 - (b) a pharmaceutically acceptable carrier.
2. (Withdrawn): The composition of claim 1, wherein the immune modulatory nucleic acid further comprises a polyG region linked 5' or 3' to the hexamer region.
3. (Withdrawn): The composition of claim 1, wherein the immune modulatory nucleic acid further comprises a first polyG region linked 5' to the hexamer region and a second polyG region linked 3' to the hexamer region.
4. (Withdrawn): The composition of claim 1, wherein the immune modulatory nucleic acid is in a sterile vial.
5. (Withdrawn): The composition of claim 1, wherein the immune modulatory nucleic acid is less than about 45 nucleotides in length.
6. (Withdrawn): The composition of claim 1, wherein the immune modulatory nucleic acid further comprises a polynucleotide region encoding self-protein(s), - polypeptide(s) or -peptide(s).

7. (Currently Amended): An nucleic acid composition comprising:
a nucleic acid vector having at least one cytosine to non-cytosine substitution within a CpG motif, ~~wherein~~ wherein the CpG motif is of the formula 5'-purine-pyrimidine-C-G-pyrimidine-pyrimidine-3' or 5'-purine-purine-C-G-pyrimidine-pyrimidine-3', and wherein the cytosine to non-cytosine substitution is within the CpG dinucleotide.

8. (Original): The nucleic acid composition of claim 7, wherein the CpG motif is of the formula 5'-purine-pyrimidine-C-G-pyrimidine-pyrimidine-3'.

9. (Original): The composition of claim 7, wherein the cytosine to non-cytosine substitution is cytosine to guanine.

10. (Original): The composition of claim 7, wherein the nucleic acid vector has a plurality of cytosine to non-cytosine substitutions.

11. (Withdrawn): A method for treating a disease in a subject associated with one or more self-molecules present non-physiologically in the subject, the method comprising:
administering to the subject an immune modulatory nucleic acid comprising a hexamer region of the formula 5'-Purine-Pyrimidine-[X]-[Y]-Pyrimidine-Pyrimidine-3', wherein X and Y are any naturally occurring or synthetic nucleotides except that X and Y cannot be cytosine-guanine.

12. (Withdrawn): The method of claim 11, wherein the immune modulatory nucleic acid further comprises a polyG region linked 5' or 3' to the hexamer region.

13. (Withdrawn): The method of claim 11, wherein the immune modulatory nucleic acid further comprises a first polyG region linked 5' to the hexamer region and a second polyG region linked 3' to the hexamer region.

14. (Withdrawn): The method of claim 11, wherein the disease is an autoimmune disease.

15. (Withdrawn): The method of claim 14, wherein the disease is multiple sclerosis.
16. (Withdrawn): The method of claim 14, wherein the disease is rheumatoid arthritis.
17. (Withdrawn): The method of claim 14, wherein the disease is insulin dependent diabetes mellitus.
18. (Withdrawn): A method for treating a disease in a subject associated with one or more self-molecules present non-physiologically in the subject, the method comprising:
administering to the subject an immune modulatory nucleic acid comprising a hexamer region of the formula 5'-Purine-Purine-[X]-[Y]-Pyrimidine-Pyrimidine-3'; wherein X and Y are any naturally occurring or synthetic nucleotides except that X and Y cannot be cytosine-guanine.
19. (Withdrawn): The method of claim 18, wherein the immune modulatory nucleic acid further comprises a polyG region linked 5' or 3' to the hexamer region.
20. (Withdrawn): The method of claim 18, wherein the immune modulatory nucleic acid further comprises a first polyG region linked 5' to the hexamer region and a second polyG region linked 3' to the hexamer region.
21. (Withdrawn): The method of claim 18, wherein the disease is an autoimmune disease.
22. (Withdrawn): The method of claim 21, wherein the disease is multiple sclerosis.
23. (Withdrawn): The method of claim 21, wherein the disease is rheumatoid arthritis.

24. (Withdrawn): The method of claim 21, wherein the disease is insulin dependent diabetes mellitus.

25. (New): The nucleic acid composition of claim 7, wherein the nucleic acid vector further comprises an immune modulatory nucleic acid comprising a hexamer region of the formula 5'-Purine-Purine-[X]-[Y]-Pyrimidine-Pyrimidine-3'; wherein X and Y are any naturally occurring or synthetic nucleotides except that X and Y cannot be cytosine-guanine.

26. (New): The method of claim 25, wherein the immune modulatory nucleic acid further comprises a polyG region linked 5' or 3' to the hexamer region.

27. (New): The method of claim 25, wherein the immune modulatory nucleic acid further comprises a first polyG region linked 5' to the hexamer region and a second polyG region linked 3' to the hexamer region.

28. (New): The nucleic acid composition of claim 7, wherein the nucleic acid vector further comprises an immune modulatory nucleic acid comprising a hexamer region of the formula 5'-Purine-Pyrimidine-[X]-[Y]-Pyrimidine-Pyrimidine-3', wherein X and Y are any naturally occurring or synthetic nucleotides except that X and Y cannot be cytosine-guanine.

29. (New): The method of claim 28, wherein the immune modulatory nucleic acid further comprises a polyG region linked 5' or 3' to the hexamer region.

30. (New): The method of claim 28, wherein the immune modulatory nucleic acid further comprises a first polyG region linked 5' to the hexamer region and a second polyG region linked 3' to the hexamer region.